Clinical Trials

We are committed to translating discoveries in the laboratory into innovative clinical trials for childhood cancer and other life-threatening diseases. 

Refer a Patient

Clinical Trials

Our scientists and doctors work around the clock to find the cures that will save children’s lives.

  

We ensure that children benefit from the remarkable advances in technology, high-throughput screening systems for new drugs and next-generation genome sequencing that identify the genetic basis for some of the most aggressive pediatric cancers. These resources have been invaluable in helping our investigators translate promising preclinical studies into definitive clinical trials.

To discuss open clinical trials at St. Jude or to refer a patient, contact our St. Jude Physician/Patient Referral Office:

Browse Clinical Trials

  1. ADV1217: WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

    Diseases Treated:

    Newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

    Eligibility:

    • Participant is > 36 month and < 21 years of age at the time of study enrollment.
    • Participant has newly diagnosed DIPG.
    • Participant has a brainstem tumor that was biopsied and proven to be one of the following: anaplastic astrocytoma, glioblastoma, gliosarcoma, or anaplastic mixed glioma.
    • Participant has not received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG. Prior dexamethasone and/or surgery are allowed.
    View Trial

    BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

    Diseases Treated:

    Solid tumors, giomas, hystiosytosis

    Eligibility:

    • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
    • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
    • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
    View Trial

    CCL0922: Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

    Diseases Treated:

    Brain Tumor : Previously treated brain tumors

    Eligibility:

    • Age is > 6 years and < 17 years & 10 months at the time of study entry.
    • Off treatment and progression–free for at least 12 months and less than and equal to 14 years.
    • Diagnosis of a primary brain tumor treated with at least one of the following :
      • Neurosurgical resection of the brain tumor;
      • Cranial irradiation;
      • Any chemotherapy to treat the brain tumor
    View Trial

    CNS1123: Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

    Diseases Treated:

    Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma

    Eligibility:

    • Participant is > 3 years and < 21 years at the time of enrollment.
    • Participant has newly diagnosed localized primary NGGCT or newly diagnosed localized germinoma (has not spread to other parts of the brain or spine).
    • Participant must have adequate bone marrow function.
    • Participant must have normal renal and liver function for age.
    • NO prior therapy except surgery and/or steroids.
    View Trial

    CNS831: Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

    Diseases Treated:

    Intracranial ependymoma

    Eligibility:

    • Patient must be greater than 12 months of age and less than 21 years of age at enrollment
    • Patients with newly diagnosed intracranial ependymoma without evidence of metastatic disease (confirmed by MRI brain and spine along with lumbar puncture to check CSF)
    • Patients with diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma are not eligible
    • No prior treatment other than surgical intervention and corticosteriods
    View Trial

    MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

    Diseases Treated:

    Refractory or refractory solid tumor

    Eligibility:

    • Participant is < 18 years at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
    • Participant has a histologically confirmed solid tumor
    • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
    View Trial

    NBTP01: Study of Stored Tumor Samples in Young Patients With Brain Tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant primary, progressive or relapsed CNS tumor of the brain and/or spine.
    • Participant is enrolled on the current version of the institution’s banking protocol.
    • Participant is less than or equal to 21 years of age at the time of the diagnosis.
    View Trial

    NBTP02: DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma

    Eligibility:

    Eligible research participants consist of St. Jude and non-St. Jude patients.

    View Trial

    PBTC29: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    Diseases Treated:

    Gliomas

    Eligibility:

    • Participant is ≥ 3 but ≤ 21 years of age at registration.
    • Participant has a diagnosis of low grade glioma (Grades I & II) or optic pathway gliomas with clinical and/or radiographic evidence of progression.
    • Participant received last fraction of local irradiation to the primary tumor ≥ 12 weeks prior to registration, or does not apply.
    View Trial

    PBTC33: Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

    Diseases Treated:

    Newly diagnosed diffuse intrinsic pontine gliomas (DIPG)

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed diffuse intrinisic pontine glioma  (DIPG)
    • Able to swallow oral medications
    • No prior treatment with chemotherapy, immumotherapy or radiation
    • No history of seizures
    View Trial

    PBTC39: Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

    Diseases Treated:

    Unresectable or recurrent craniopharyngioma

    Eligibility:

    • Participant has a histologically verified diagnosis of craniopharyngioma.
    • Participant has recovered from acute toxicities of all prior therapy before entering this study.
    • Participant has not received prior interferon, either systemic or into the tumor cyst.
    • Participant does not have evidence of metastatic tumor.
    View Trial

    PBTC42: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

    Diseases Treated:

    Retinoblastoma protein 1 (Rb1) positive recurrent, progressive, or refractory central nervous system tumors

    Eligibility:

    • Participant between four (4) and twenty-one (21) years of age at time of enrollment.
    • Participant has histologically confirmed Rb1 positive recurrent, progressive, or refractory CNS tumor or DIPG.
    • Participant with a neurological deficit that is stable for at least one (1) week prior to enrollment.
    • Participant has received last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to enrollment.
    • Participant has received last fraction of focal irradiation > two (2) weeks prior to enrollment.
    View Trial

    PNOC001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children (CC #120817)

    Diseases Treated:

    Recurrent or progressive low grade gliomas (brain tumors)

    Eligibility:

    • Participant is three (3) to twenty-one (21) years of age.
    • Patient has refractory, progressive or recurrent confirmed low-grade glioma (WHO grade I or II) that was confirmed histologically at initial diagnosis.
    • Participant received his or her last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration, or at least six (6) weeks if nitrosurea.
    • Participant received his or her last dose of other investigational or biological agent more than seven (7) days prior to study entry.
    View Trial

    PNOC002: A Safety Phase 0, and Pilot Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E in Children with Recurrent/Refractory BRAFV600E-Mutant Brain Tumors [PNOC-002, CC #120819, IND#116870 (exempt)]

    Diseases Treated:

    Brain Tumors (Recurrent and Refractory)

    Eligibility:

    • Participant enrolling on the MTD cohort is less than eight-teen (18) years of age at registration or if enrolling on the expansion cohort is less than or equal to twenty-five (25) years of age at time of registration.
    • Participant has histologically confirmed diagnosis of glioma (WHO Grades I-IV).
    • Participant tumor has tested positive for the BRAFV600E mutation at a CLIA approved laboratory.
    View Trial

    RERTEP: Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma

    Diseases Treated:

    Recurrent ependymoma

    Eligibility:

    • Participant aged 1-21 years at the time of enrollment.
    • Participant has histologically proven progressive Ependymoma after prior focal irradiation.
    • Participant did not receive prior craniospinal irradiation.
    • Participant is not pregnant.
    View Trial

    RT2CR: Limited Surgery and Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years of age or younger
    • Diagnosis of craniopharyngioma 
    • Has not been previously treated with radiation therapy
    View Trial

    SJATRT: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

    Diseases Treated:

    Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
    Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

    Eligibility:

    • Has one of these types of tumors:
      • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
      • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
      • ATRTs or MRTs that are growing after previous treatment (progressive disease)
    • 21 years of age or younger
    View Trial

    SJHG12: Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma

    Diseases Treated:

    Progressive or recurrent pontine glioma or high-grade glioma

    Eligibility:

    • Between 2 and 21 years of age
    • Diagnosis of diffuse intrinsic pontine glioma (DIPG) or high-grade glioma
    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • Must be least 3 but not more than 22 years of age
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial

    SJYC07: Risk-Adapted Therapy in Treating Young Children with Brain Tumors

    Diseases Treated:

    ATRT, PNET, medulloblastoma and other embryonal brain tumors, high-grade glioma, choroid plexus carcinoma or ependymoma

    Eligibility:

    • Newly diagnosed brain tumor or tumor of the central nervous system and less than 3 years of age
    • Children between 3 and 5 years old with medulloblastoma  that has not spread  into the fluid that surrounds the brain and spinal cord can also be treated on this trial
    • No prior radiation therapy or chemotherapy
    View Trial
  2. ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    A Phase I Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    Diseases Treated:

    Relapsed or refractory solid tumors or anaplastic large cell lymphoma

    Eligibility:

    • Participant is > than 12 month and < 21 years of age at the time of enrollment.
    • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
    • Participant does not have primary or metastatic CNS tumor.
    • Participant has not received prior therapy with crizotinib.
    View Trial

    ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

    A Phase I/II Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan In Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors

    Eligibility:

    • Participant is >12 months and < 21 years of age at the time of study entry.
    • Participant has had histologic verification of malignancy at original diagnosis or relapse.
    • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
    • Participant has a relapsed or refractory solid tumor.
    View Trial

    ADV912: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-MET, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

    Diseases Treated:

    Relapses/refractory solid tumors and anaplastic large cell lymphoma

    Eligibility:

    • Patient should be greater than 12 months and less than or equal to 21 years of age at the time of study enrollment.
    • Patients with relapsed or refractory neuroblastoma and anaplastic larger cell lymphoma are eligible.
    • Patients who are currently receiving another investigational drug and patients with uncontrolled infection are not eligible.
    View Trial

    ANBLB1: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Neuroblastoma Biology Studies

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • All newly diagnosed suspected:
      • neuroblastoma,
      • ganglioneuroblastoma, or 
      • ganglioneuroma (maturing subtype) patients
    • Less than or equal to 21 years of age
    • Seen at Children's Oncology Group (COG) institutions
    View Trial

    ASCIST: Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High-Risk Solid Tumors or Lymphomas

    A Phase I Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+Positively-Selected Autologous Hematopoietic Stem Cells In Children With High-Risk Solid Tumors or Lymphomas

    Diseases Treated:

    High-risk solid tumors and lymphomas

    Eligibility:

    • Has a type of high-risk cancer including
      • Neuroblastoma
      • Solid tumors
      • Lymphomas
    • 21 years of age or younger
    • Has not received a prior hematopoietic (blood cells from bone marrow) stem cell transplant within the previous three months
    View Trial

    BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

    Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Debrafenib in Children and Adolescent Subjects with Advance BRAF V600-Mutation Positive Solid Tumors

    Diseases Treated:

    Solid tumors, giomas, hystiosytosis

    Eligibility:

    • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
    • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
    • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
    View Trial

    DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy. 
    • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
    • Participant meets institutional MRI safety screening requirements. 
    • Participant has not undergone primary tumor resection prior to arrival to St. Jude
    View Trial

    ESFT13: Therapeutic Trial for Patients with Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors

    Combination Chemotherapy with or without Sorafenib Tosylate and Bevacizumab in Treating Patients with Ewing Sarcoma or Desmoplastic Small Round Cell Tumors

    Diseases Treated:

    Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors

    Eligibility:

    • Diagnosis of Ewing sarcoma and/or desmoplastic small round cell tumor (DSRCT)
    • Less than 25 years of age
    • Has not received previous treatment with radiation therapy or chemotherapy. Emergent radiation therapy to preserve vital organ function is permitted.
    View Trial

    IPACTR: International Pediatric Adrenocortical Tumor Registry

    Diseases Treated:

    Adrenocortical carcinoma

    Eligibility:

    • Diagnosis of an adrenocortical tumor (ACT)
    • 21 years of age or younger
    • Relatives of patients with ACT
    View Trial

    LDKALK: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

    A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Novartis Protocol CLDK378X2103

    Diseases Treated:

    Refractory or progressive malignancies

    Eligibility:

    • Age > 12 months and < 18 years.
    • Participant has been diagnosed with a locally advanced or metastatic malignancy that has progressed despite standard therapy, or which no effective standard therapy exists.
    • Specimen is being submitted for molecular pre-screening to test for genetic alteration of ALK and the tumor must carry a genetic alteration of the ALK gene.
    • Participant has adequate liver, kidney, cardiac, and bone marrow function.
    View Trial

    LITE: Light Therapy to Increase Energy in Adolescents with Solid Tumors: A Pilot Study

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is between the ages of twelve (12) and eighteen (18) years old. 
    • Participant has been diagnosed with a solid tumor within the past thirty (30) days. 
    • Participant is not blind and does not have a history of eye disease including, but not limited to macular degeneration, or other diagnosed retinal problems. 
    • Participant has not initiated antidepressant medication, including either SSRIs in the past month, and MAOIs in the past two months. 
    • Participant has not undergone laser corrective eye surgery in the past thirty (30) days.
    View Trial

    MARB: Molecular Analysis of Retinoblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

    An Open- Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations.

    Diseases Treated:

    Refractory or refractory solid tumor

    Eligibility:

    • Participant is < 18 years at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
    • Participant has a histologically confirmed solid tumor
    • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
    View Trial

    MEKPEM: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma

    (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or  lymphoma

    Eligibility:

    • Participant has advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
    • Participant of child bearing potential has a negative pregnancy test 72 hours prior to medication administration
    • Participant has appropriate liver and kidney function
    View Trial

    MELBMS: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

    Diseases Treated:

    Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma

    Eligibility:

    • Participant does not have a history of or current immunodeficiency disease, splenectomy or splenic irradiation
    • Participant does not have primary ocular melanoma
    • Participant does not have an uncontrolled infectious disease
    • Participant has not had a prior allogeneic stem cell transplant
    View Trial

    MELPLX: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

    An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of RO5185426 in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600

    Diseases Treated:

    Melanoma

    Eligibility:

    • Patients may have newly diagnosed or recurrent melanoma
    • Patients with histologically confirmed surgically incurable and unresectable Stage IIIC or Stage IV (AJCC) melanoma
    • Patients aged ≥ 12 to ≤ 17 years
    • Patients with active or untreated CNS lesions or history of or known spinal cord compression or carcinomatous meningitis or history of allogeneic bone marrow transplantation or organ transplantation are not eligible for the study

     

    View Trial

    NB2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

    Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    • Participant is < 19 years of age at the time of study enrollment.
    • Participant has newly diagnosed, advanced stage, high-risk neuroblastoma.
    • Participant has histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine.
    • Participant has adequate renal and hepatic function.
    View Trial

    NBL1232: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-High Risk Neuroblastoma

    Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (ANBL1232)

    Diseases Treated:

    Neuroblastoma, ganglioneuroblastoma

    Eligibility:

    • Participant has been enrolled on ANBLB1 (ANBL00B1).
    • Participant has newly diagnosed MYCN non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma.
    • Participant is less than 12 months (Group A) and less than 18 months (Group B and Group C) of age at diagnosis.

     

    View Trial

    PDMCRN: Parental Decision-Making for Children with Relapsed Neuroblastoma

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is the parent of a child with relapsed or refractory high risk neuroblastoma receiving primary oncology care or a second opinion at a participating site.
    • Parent aged 18 year or older, of a child aged ≤ 18 years.
    • Participating parent if the primary decision maker for the family.
    • Participating parent is English-speaking.
    View Trial

    RADIANT: Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas

    A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation In Children with Relasped or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors or lymphomas

    Eligibility:

    • Between the ages of 2 and 21 years
    • Solid tumor or lymphoma as primary cancer
    • Cancer that has come back or did not respond to previous chemotherapy
    • No heart, kidney or liver problems
    View Trial

    RMS13: Chemotherapy, Surgery, and Radiation Therapy in Treating Patients with Newly Diagnosed, Localized Rhabdomyosarcoma

    Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients with Low and Intermediate Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    Diseases Treated:

    Rhabdomyosarcoma (Low-risk and intermediate-risk)

    Eligibility:

    • Must have newly diagnosed rhabdomyosarcoma
    • Less than 22 years of age
    • Has not received previous treatment with chemotherapy or radiation therapy
    View Trial

    RST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery

    Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) (ARST1321)

    Diseases Treated:

    Non-rhabdomyosarcoma soft tissue

    Eligibility:

    • > 2 years at the time of the biopsy that established the diagnosis of NRSTS.
    • Participant has a NRSTS in the extremity or trunk.
    • Participant has adequate bone marrow function.
    • Participant has not had prior Anthracycline or Ifosfamide therapy.
    • Participant is not HIV-positive.
    View Trial

    SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

    A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

    Diseases Treated:

    Metastatic sarcomas

    Eligibility:

    • Participant has histologically or cytologically confirmed diagnosis:
      • Nonrhabdomyosarcoma of soft tissue
      • Ewing sarcoma
      • Osteosarcoma at any site
    • Participant must be greater than 3 years of age and < 40 years of age.
    • Participant has not had any prior radiotherapy to the treatment site.
    View Trial

    SJATRT: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

    Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

    Diseases Treated:

    Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
    Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

    Eligibility:

    • Has one of these types of tumors:
      • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
      • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
      • ATRTs or MRTs that are growing after previous treatment (progressive disease)
    • 21 years of age or younger
    View Trial

    SJGD2: Monoclonal Antibody Therapy in Treating Younger Patients with Relapsed or Refractory Neuroblastoma, Osteosarcoma, or Melanoma

    A Phase I Trial of the Humanized Anti-GD2 Antibody(HU14.18K322A) in Children and Adolescents with Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

    Diseases Treated:

    Neuroblastoma, osteosarcoma, melanoma or Ewing sarcoma

    Eligibility:

    • Up to 21 years of age
    • Diagnosis of neuroblastoma, melanoma, osteosarcoma  or Ewing sarcoma that has come back or did not respond to previous treatment
    • Any uncontrolled infection
    View Trial

    SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

    Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • Newly diagnosed retinoblastoma that has not spread beyond the eye
    • Has not received previous treatment with chemotherapy or radiation therapy
    • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
    View Trial
  3. ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    A Phase I Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    Diseases Treated:

    Relapsed or refractory solid tumors or anaplastic large cell lymphoma

    Eligibility:

    • Participant is > than 12 month and < 21 years of age at the time of enrollment.
    • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
    • Participant does not have primary or metastatic CNS tumor.
    • Participant has not received prior therapy with crizotinib.
    View Trial

    ADV912: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-MET, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

    Diseases Treated:

    Relapses/refractory solid tumors and anaplastic large cell lymphoma

    Eligibility:

    • Patient should be greater than 12 months and less than or equal to 21 years of age at the time of study enrollment.
    • Patients with relapsed or refractory neuroblastoma and anaplastic larger cell lymphoma are eligible.
    • Patients who are currently receiving another investigational drug and patients with uncontrolled infection are not eligible.
    View Trial

    ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

    Eligibility:

    • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
      • Come back after treatment the first time
      • Did not respond to treatment the first time
    • Less than 22 years of age
    • Does not have HIV or hepatitis B infection
    View Trial

    AML08: Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

    A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

    Diseases Treated:

    Acute myeloid leukemia (AML)

    Eligibility:

    • 21 years of age or younger at the time of study entry
    • No prior therapy for AML except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine for hyperleukocytosis
    • Must not have Down syndrome, acute promyelocytic leukemia (APL), juvenile myelomonocytic leukemia (JMML), Fanconi anemia (FA), Kostmann syndrome, Shwachman syndrome and other  bone marrow failure syndromes
    View Trial

    ASCIST: Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High-Risk Solid Tumors or Lymphomas

    A Phase I Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+Positively-Selected Autologous Hematopoietic Stem Cells In Children With High-Risk Solid Tumors or Lymphomas

    Diseases Treated:

    High-risk solid tumors and lymphomas

    Eligibility:

    • Has a type of high-risk cancer including
      • Neuroblastoma
      • Solid tumors
      • Lymphomas
    • 21 years of age or younger
    • Has not received a prior hematopoietic (blood cells from bone marrow) stem cell transplant within the previous three months
    View Trial

    BECHEM: Bendamustine, Clofarabine and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies

    A Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies

    Diseases Treated:

    Relapsed or refractory hematologic malignancies

    Eligibility:

    • Diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma or leukemia that has come back or did not respond to treatment
    • Must be 21 years of age or younger at the time of enrollment
    • Must have adequate kidney and heart function 
    View Trial

    CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients

    A Phase III Trial of Calfactant for Acute Lung Injury in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Patients

    Diseases Treated:

    Acute respiratory distress (ARDS) / acute lung injury (ALI)

    Eligibility:

    • Patient is 18 months of age to 25 years.
    • Patient has a diagnosis of Leukemia/Lymphoma undergoing active treatment or following HSCT.
    • Patients with chronic lung disease or congenital heart disease are not eligible for the study.
    View Trial

    DVALL: Leukemia Lymphoma Clinical Trial: A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

    A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (TACL protocol T2009-003)

    Diseases Treated:

    Relapsed ALL

    Eligibility:

    • Participant is equal to or greater of 1 year of age and less or equal to 25 years of age at the time of study enrollment. 
    • Participant has a diagnosis of acute lymphoblastic leukemia (ALL) with > 25% blasts in the bone marrow (M3), with or without extramedullary disease.
    • Participants may have CNS 1, 2 or 3 disease.
    View Trial

    HLHR13: Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma

    Adcetris® (Brentuximab Vedotin) Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High-Risk Pediatric Hodgkin Lymphoma (HL)

    Diseases Treated:

    High-risk Hodgkin lymphoma

    Eligibility:

    • Has high-risk Hodgkin lymphoma
    • 18 years of age or younger
    • Has not received previous treatment for Hodgkin lymphoma
    View Trial

    HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

    Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    • Diagnosis of early-stage Hodgkin lymphoma 
    • Hodgkin lymphoma that has not been previously treated
    • 21 years of age or younger
    View Trial

    HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children and Adolescents

    Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

    Diseases Treated:

    Lymphocyte predominant Hodgkin lymphoma 

    Eligibility:

    • Diagnosis of early-stage lymphocyte-predominant Hodgkin lymphoma (LPHL)
    • LPHL that has not been previously treated with chemotherapy or radiation therapy
    • 18 years of age or younger

     

    View Trial

    LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

    Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    For survivors of Hodgkin lymphoma

    Eligibility:

    • Females, 25 years of age or older.
    • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
    View Trial

    LiSTENING: Learning in Story: Elicited Narrative Informs Navigating Genetics

    Eligibility:

    This is a non-therapeutic clinical trial open to St. Jude patients only.

    Participants have been pre-identified by the primary care team as an English-speaking, four-member family unit diagnosed with TP53 mutation.

    View Trial

    MEKPEM: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma

    (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or  lymphoma

    Eligibility:

    • Participant has advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
    • Participant of child bearing potential has a negative pregnancy test 72 hours prior to medication administration
    • Participant has appropriate liver and kidney function
    View Trial

    MITREL: A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

    A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

    Diseases Treated:

    Refractory or relapsed acute myeloid leukemia (AML), myelodysplatic syndrome (MDS), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia (MPAL)

    Eligibility:

    • Patient should be is less than or equal to twenty-one years of age.
    • Patient has a diagnosis of AML, MDS, ALL, or MPAL that has relapsed or is refractory to chemotherapy or has relapsed after HSCT.
    • Patient has an available PBSC donor.
    View Trial

    NCBP01: Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation

    A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

    Diseases Treated:

    Leukemia and other blood diseases

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU).
    • Participant may be of any age and either gender.
    • Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
    • Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
    View Trial

    NECTAR: Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

    A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC

    Diseases Treated:

    Leukemia

    Eligibility:

    • Patients must be ≥ 1 and ≤ 21 years of age at the time of study enrollment.
    • Patients must have first relapse T-cell ALL or T-cell lymphoblastic lymphoma.
    • Patients with T-cell ALL must have greater than 25% blasts in the bone marrow with or without extramedullary disease.
    • Patients with T-cell ALL must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis.
    View Trial

    NHL16: Study for Newly Diagnosed Patients with Acute Lymphoblastic Lymphoma

    Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Lymphoma

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed lymphoblastic lymphoma
    • Has received one week or less prior treatment for lymphoblastic lymphoma
    View Trial

    PANSTAT: A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

    A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies

    Diseases Treated:

    Relapsed acute lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin disease [HD] and non-Hodgkin’s lymphomas [NHL]

    Eligibility:

    • Patient must be greater than 1 and less than or equal to 21 years of age at the time of enrollment;
    • Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
    • Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.
    View Trial

    RADIANT: Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas

    A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation In Children with Relasped or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors or lymphomas

    Eligibility:

    • Between the ages of 2 and 21 years
    • Solid tumor or lymphoma as primary cancer
    • Cancer that has come back or did not respond to previous chemotherapy
    • No heart, kidney or liver problems
    View Trial

    RELHEM: Sorafenib Tosylate, Cytarabine, and Clofarabine in Treating Patients with Refractory or Relapsed Hematologic Malignancies

    A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies

    Diseases Treated:

    Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia

    Eligibility:

    • Patient must have acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (either AML or ALL), AML with prior myelodysplastic syndrome (MDS),myelodysplastic/myeloproliferative neoplasms, or biphenotypic leukemia.
    • Patients must meet one of the following criteria:
      • First or greater relapse
      • Refractory to 1 or more courses of induction or reinduction chemotherapy
      • First or greater relapse after allogeneic hematopoietic stem cell transplantation (HSCT).

     

    View Trial

    RELHEM2: Crenolanib and Sorafenib Tosylate in Treating Patients with Refractory or Relapsed Hematologic Malignancies

    A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination with Sorafenib in Patients with Refractory or Relapsed Hematologic Malignancies (ARO-008)

    Diseases Treated:

    Refractory or relapsed hematologic malignancies (leukemia)

    Eligibility:

    • Between the ages of 1 and 25 years
    • FLT3-mutated AML that has returned or did not respond to previous chemotherapy
    • No history of HIV infection, hepatitis B, or hepatitis C
    View Trial

    RELMLL: A Phase II Study of Bortezomib and Vorinostat in Patients with Refractory or Relapsed MLL Rearranged Hematologic Malignancies

    Diseases Treated:

    Relapsed or refractory leukemia / lymphoma

    Eligibility:

    This clinical trial has both inclusion and exclusion criteria. See Eligibility Requirements in the full trial for specifics.

    View Trial

    SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Diseases Treated:

    Relapsed or refractory leukemia or hematologic malignancies

    Eligibility:

    • Up to 21 years of age
    • Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back or did not respond to previous treatment
    • No history of HIV infection
    View Trial

    SJBC3: Mature B-cell Lymphoma and Leukemia Study III

    Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia

    Diseases Treated:

    Leukemia and lymphoma

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed mature B-cell non-Hodgkin lymphoma and leukemia
    • Has not been previously treated
    View Trial

    TOTXVI: Total Therapy Study XVI For Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

    Diseases Treated:

    Acute Lymphoblastic Leukemia

    Eligibility:

    • 18 years of age or younger
    • Newly diagnosed acute lymphoblastic leukemia (ALL)
    View Trial
  4. EPSTRV: Retroviral Vector Mediated Globin Gene Transfer to Correct Sickle Cell Anemia or Thalassemia

    Experimental Evaluation of the Potential to Correct the Pathophysiology of Sickle Cell Anemia or Thalassemia by Retroviral Vector Mediated Globin Gene Transfer

    Diseases Treated:

    Sickle cell anemia

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Age 5 years old or older
    • No active sickle cell disease
    • Adequate blood counts
    View Trial

    SCCRIP: Sickle Cell Research and Intervention Program

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant has a diagnosis of Sickle Cell Disease of any genotype.
    • Participant is 1 day to 24.9 years of age.
    View Trial

    TADO: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

    A Phase 3 Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    • Participant with Sickle Cell Disease (laboratory determined HbSS or HbS beta zero thalassemia) who have had >2 episodes of Vaso-occlusive crisis in the past year. 
    • Participants >2 years of age and < 18 years of age.
    View Trial
  5. BECHEM: Bendamustine, Clofarabine and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies

    A Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies

    Diseases Treated:

    Relapsed or refractory hematologic malignancies

    Eligibility:

    • Diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma or leukemia that has come back or did not respond to treatment
    • Must be 21 years of age or younger at the time of enrollment
    • Must have adequate kidney and heart function 
    View Trial

    CPPGAL: Characterization of the Patient Population with Galactosialidosis

    Diseases Treated:

    Galactosialidosis

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    ED0157: Phase 1 Pediatric PK/PD Study

    A Phase I, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

    Diseases Treated:

    For patients at risk for blood clots

    Eligibility:

    • Participant has a diagnosis requiring anticoagulant therapy.
    • Participant has completed their standard anticoagulant therapy.
    • Participant is not receiving active therapy for a malignant condition.
    • Participant is less than 18 years of age at the time of consent.
    • Participant and legal guardian agree to food and drug restrictions during study.
    View Trial

    EPSTRV: Retroviral Vector Mediated Globin Gene Transfer to Correct Sickle Cell Anemia or Thalassemia

    Experimental Evaluation of the Potential to Correct the Pathophysiology of Sickle Cell Anemia or Thalassemia by Retroviral Vector Mediated Globin Gene Transfer

    Diseases Treated:

    Sickle cell anemia

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Age 5 years old or older
    • No active sickle cell disease
    • Adequate blood counts
    View Trial

    GENIOS: Genes Influencing Iron Overload State

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Patients who have iron overload from too many blood transfusions will be eligible for this study.
    • Patients who are still receiving blood transfusions and patients who are not regularly receiving blood transfusion anymore, but still need treatment to remove blood from their bodies will be eligible for this study.
    • The patient will not be eligible for the study if he/she has any known contraindication to performance of MRI.
    View Trial

    HIRS: Hemophilia Inhibitor Research Study Phase III

    Diseases Treated:

    Hemophilia (non-therapeutic)

    Eligibility:

    Study Arm I

    • Participant is male age two (2) or older (Study Arm I) or of any age and any race/ethnicity (Study Arm II)
    • Participant has a diagnosis of Hemophilia A (Study Arm I) or Hemophilia A or B (Study Arm II) with a baseline factor activity level less than 50% of normal.
    • Participant has not participated in HIRS Phase I or Phase II (Study Arm I)
    View Trial

    LVXSCID-ND: Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

    A Pilot Feasibility Study of Gene Transfer For X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector To Transduce Autologous CD34 + Hematopoietic Cells

    Diseases Treated:

    X-linked Severe Combined Immunodeficiency (SCID-X1)

    Eligibility:

    • Diagnosis of Severe Combined Immunodeficiency Disease, X-linked (SCID-X1)
    • Newborn to 12 months of age
    • No prior therapy with allogeneic stem cell transplantation
    • No HIV infection
    View Trial

    MIDAS: Massive Iron Overload Assessment

    Diseases Treated:

    Iron overload 

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant has a history of 12 or more lifetime erythrocyte transfusions.
    • Participant has a need for liver iron content assessment.
    • No contra-indication to having an MRI exam, such as the presence of metal in the body.
    View Trial

    PKiDS: Pyruvate Kinase Deficiency (PKD) Natural History Study

    Diseases Treated:

    Pyruvate kinase deficiency (PKD)

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participants of all ages with biochemically or genetically diagnosed PKD.
    • Participants with a hemolytic anemia and a family member with genetically diagnosed PKD.
    • The participant or the guardian of the participant is willing and able to give written informed consent and/or assent.
    View Trial

    RELHEM: Sorafenib Tosylate, Cytarabine, and Clofarabine in Treating Patients with Refractory or Relapsed Hematologic Malignancies

    A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies

    Diseases Treated:

    Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia

    Eligibility:

    • Patient must have acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (either AML or ALL), AML with prior myelodysplastic syndrome (MDS),myelodysplastic/myeloproliferative neoplasms, or biphenotypic leukemia.
    • Patients must meet one of the following criteria:
      • First or greater relapse
      • Refractory to 1 or more courses of induction or reinduction chemotherapy
      • First or greater relapse after allogeneic hematopoietic stem cell transplantation (HSCT).

     

    View Trial

    RELHEM2: Crenolanib and Sorafenib Tosylate in Treating Patients with Refractory or Relapsed Hematologic Malignancies

    A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination with Sorafenib in Patients with Refractory or Relapsed Hematologic Malignancies (ARO-008)

    Diseases Treated:

    Refractory or relapsed hematologic malignancies (leukemia)

    Eligibility:

    • Between the ages of 1 and 25 years
    • FLT3-mutated AML that has returned or did not respond to previous chemotherapy
    • No history of HIV infection, hepatitis B, or hepatitis C
    View Trial

    RELMLL: A Phase II Study of Bortezomib and Vorinostat in Patients with Refractory or Relapsed MLL Rearranged Hematologic Malignancies

    Diseases Treated:

    Relapsed or refractory leukemia / lymphoma

    Eligibility:

    This clinical trial has both inclusion and exclusion criteria. See Eligibility Requirements in the full trial for specifics.

    View Trial

    SCCRIP: Sickle Cell Research and Intervention Program

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant has a diagnosis of Sickle Cell Disease of any genotype.
    • Participant is 1 day to 24.9 years of age.
    View Trial

    SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Diseases Treated:

    Relapsed or refractory leukemia or hematologic malignancies

    Eligibility:

    • Up to 21 years of age
    • Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back or did not respond to previous treatment
    • No history of HIV infection
    View Trial

    TADO: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

    A Phase 3 Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease

    Diseases Treated:

    Sickle cell disease

    Eligibility:

    • Participant with Sickle Cell Disease (laboratory determined HbSS or HbS beta zero thalassemia) who have had >2 episodes of Vaso-occlusive crisis in the past year. 
    • Participants >2 years of age and < 18 years of age.
    View Trial

    TRIALS: Transfusional Iron Overload Among Leukemia Survivors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial
  6. AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy

    Diseases Treated:

    HIV Infection

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • The subject has been enrolled on IMPAACT P1025.
    View Trial

    ATN129: Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

    Comparing the Effectiveness of Two Alcohol+Adherence Interventions For HIV+ Youth (Healthy Choices 2; HC2)

    Diseases Treated:

    HIV

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant receives services at St. Jude.
    • Participant has HIV-1 Infection.
    • Participant is between the ages of 16 years and 24 years.
    • Participant has been offered a prescription for antiretroviral (ARV) medications.
    • Participant is able to understand, read, and speak English.
    • Participant has used alcohol in the last 12 weeks prior to screening.
    View Trial

    CaRMA: Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study

    Eligibility:

    • This is a non-therapeutic clinical trial that is only open to St. Jude patients.
    • Participant is receiving treatment for any disease at St. Jude.
    • Participant is age ≥ 5 years to < 25 years.
    • Participant has single or double lumen tunneled CVAD (ports not eligible).
    • Participant’s treating clinician does not plan to remove CVAD within 12 weeks.
    • Participant has not been previously enrolled in the CaRMA study or had past catheter resistance monitoring.
    View Trial

    CCL1034: Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

    Diseases Treated:

    Cancer or allogeneic hematopoietic cell transplantation

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant > 2 months of age and < 21 years of age at enrollment.
    • Participant has or is scheduled to have an external tunneled central venous catheter (CVC) (Broviacs, Hickmans, tunneled percutaneously inserted central PICCs), that is expected to remain in place for an additional > 3 months.
    • Participant with a current or previous line infection completed antibiotics > 14 days ago.
    View Trial

    CMX304: A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

    A phase 3, Open-Label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated Adenovirus Disease

    Diseases Treated:

    Adenovirus

    Eligibility:

    • Participant is male or female, aged 2 months or older.
    • Participant is asymptomatic with AdV infection but is at risk of progression or has localized AdV disease
      OR
    • Participant has disseminated AdV disease.

     

    View Trial

    DASRAN: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

    Diseases Treated:

    Parainfluenza virus in immunocompromised patients

    Eligibility:

    • Participant is >12 years of age.
    • Participant is currently on invasive mechanical ventilation or noninvasive positive pressure ventilation or requiring > 2 LPM supplemental oxygen to maintain O2 saturation > 90% due to hypoxemia.
    • Participant is Immunocompromised, as defined by one of the following:
      • Autologous or Allogeneic hematopoietic cell transplantation (HSCT).
      • Lung or lung-heart transplantation.
      • Participant is treated with chemotherapy for hematologic or solid tumor malignancies.
    View Trial

    ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

    A Phase 2/3 multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects

    Diseases Treated:

    HIV Infection

    Eligibility:

    • Participant does not have life expectancy of less than 1 year.
    • Participant does not have history of significant drug sensitivity or drug allergy.
    • Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
    • Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
    View Trial

    ETHEL: Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

    A Double-Blind, Randomized, Placebo-Controlled, Trial of Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line Associated Bloodstream Infection (CLABSI) in Children and Adolescents

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is ≥ 6 months and < 25 years of age and is ≥ 5 kg.
    • Participant has new diagnosis of central line associated blood stream infection with a silicone catheter (ports, and Broviac or Hickman lines will be eligible).
    • Participant has not received ELT in the preceding 2 weeks.
    • Participant does not have multiple long-term central lines.
    View Trial

    GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen

    A Phase 2/3, Open-Label Multi- Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a Tenofovir Disoproxil Fumarate (TDF)-Containing Regimen, Initial Version, June 23, 2014

    Diseases Treated:

    HIV/AIDS

    Eligibility:

    • Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
    • Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
    • Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
    View Trial

    GS1515: Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

    A Phase II/III, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents

    Diseases Treated:

    HIV/AIDS

    Eligibility:

    • Participant is twelve (12) to less than eighteen (18) years of age at Baseline.
    • Participant does not have a new AIDS defining condition diagnosed within thirty (30) days prior to Screening.
    • Participant does not have evidence of active pulmonary or extra-pulmonary tuberculosis disease within three (3) months of the
    View Trial

    INMED: Investigation of Incentives to Promote Medication Adherence Among HIV- Infected Adolescents on Antiretroviral Therapy.

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is > 16 and < 24 years of age.
    • Participant is diagnosed with HIV.
    • Participant is aware of his/her HIV diagnosis.
    • Participant understands either written or spoken English.
    View Trial

    P1093: Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents

    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

    Diseases Treated:

    Human Immunodeficiency Virus

    Eligibility:

    • Participant is ≥ 4 weeks to < 18 years of age.
    • Confirmed HIV-1 infection
    • HIV treatment experienced (current or past treatment with HIV medications) patient
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Diseases Treated:

    Croup

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial
  7. ADV1212: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    A Phase I Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    Diseases Treated:

    Relapsed or refractory solid tumors or anaplastic large cell lymphoma

    Eligibility:

    • Participant is > than 12 month and < 21 years of age at the time of enrollment.
    • Participant has histologic verification at original diagnosis or relapse or relapse of relapsed or refractory solid tumor or anaplastic large cell lymphoma (ALCL).
    • Participant does not have primary or metastatic CNS tumor.
    • Participant has not received prior therapy with crizotinib.
    View Trial

    ADV1217: WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

    A Phase I Study of MK-1775 (IND#116459) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas

    Diseases Treated:

    Newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

    Eligibility:

    • Participant is > 36 month and < 21 years of age at the time of study enrollment.
    • Participant has newly diagnosed DIPG.
    • Participant has a brainstem tumor that was biopsied and proven to be one of the following: anaplastic astrocytoma, glioblastoma, gliosarcoma, or anaplastic mixed glioma.
    • Participant has not received any prior chemotherapy, radiation therapy, immunotherapy or bone marrow transplant for the treatment of DIPG. Prior dexamethasone and/or surgery are allowed.
    View Trial

    ADV1312: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

    A Phase I/II Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan In Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors

    Eligibility:

    • Participant is >12 months and < 21 years of age at the time of study entry.
    • Participant has had histologic verification of malignancy at original diagnosis or relapse.
    • Participant has serum tumor markers including alpha-fetoprotein or beta-HCG.
    • Participant has a relapsed or refractory solid tumor.
    View Trial

    ADV912: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

    A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-MET, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

    Diseases Treated:

    Relapses/refractory solid tumors and anaplastic large cell lymphoma

    Eligibility:

    • Patient should be greater than 12 months and less than or equal to 21 years of age at the time of study enrollment.
    • Patients with relapsed or refractory neuroblastoma and anaplastic larger cell lymphoma are eligible.
    • Patients who are currently receiving another investigational drug and patients with uncontrolled infection are not eligible.
    View Trial

    ALLR18: Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

    Diseases Treated:

    Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

    Eligibility:

    • B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has:
      • Come back after treatment the first time
      • Did not respond to treatment the first time
    • Less than 22 years of age
    • Does not have HIV or hepatitis B infection
    View Trial

    ASCIST: Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High-Risk Solid Tumors or Lymphomas

    A Phase I Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+Positively-Selected Autologous Hematopoietic Stem Cells In Children With High-Risk Solid Tumors or Lymphomas

    Diseases Treated:

    High-risk solid tumors and lymphomas

    Eligibility:

    • Has a type of high-risk cancer including
      • Neuroblastoma
      • Solid tumors
      • Lymphomas
    • 21 years of age or younger
    • Has not received a prior hematopoietic (blood cells from bone marrow) stem cell transplant within the previous three months
    View Trial

    BECHEM: Bendamustine, Clofarabine and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies

    A Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies

    Diseases Treated:

    Relapsed or refractory hematologic malignancies

    Eligibility:

    • Diagnosis of Hodgkin lymphoma, non-Hodgkin lymphoma or leukemia that has come back or did not respond to treatment
    • Must be 21 years of age or younger at the time of enrollment
    • Must have adequate kidney and heart function 
    View Trial

    BRF116: A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

    Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Debrafenib in Children and Adolescent Subjects with Advance BRAF V600-Mutation Positive Solid Tumors

    Diseases Treated:

    Solid tumors, giomas, hystiosytosis

    Eligibility:

    • Participant is greater or equal to 12 months and less than 18 years at the time of signing the informed consent form.
    • Participant has BRAF V600 mutation positive tumor as confirmed in a CLIA-approved laboratory or equivalent
    • Participant has recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease, OR participant has metastatic (or surgically unresectable) melanoma, and is being enrolled for first-line treatment. Melanoma participants with CNS involvement may be enrolled.
    View Trial

    CCL0922: Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

    A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor (SCUSF 0901; ACCL0922)

    Diseases Treated:

    Brain Tumor : Previously treated brain tumors

    Eligibility:

    • Age is > 6 years and < 17 years & 10 months at the time of study entry.
    • Off treatment and progression–free for at least 12 months and less than and equal to 14 years.
    • Diagnosis of a primary brain tumor treated with at least one of the following :
      • Neurosurgical resection of the brain tumor;
      • Cranial irradiation;
      • Any chemotherapy to treat the brain tumor
    View Trial

    CNS1123: Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

    Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

    Diseases Treated:

    Newly diagnosed localize primary NGGCT or newly diagnosed localized germinoma

    Eligibility:

    • Participant is > 3 years and < 21 years at the time of enrollment.
    • Participant has newly diagnosed localized primary NGGCT or newly diagnosed localized germinoma (has not spread to other parts of the brain or spine).
    • Participant must have adequate bone marrow function.
    • Participant must have normal renal and liver function for age.
    • NO prior therapy except surgery and/or steroids.
    View Trial

    CSqHPV: Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

    Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial A Consortium for Pediatric Interventional Research

    Diseases Treated:

    Human papillomavirus

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    Questionnaire phase

    • Cancer survivor (9 to 26 years of age at study participation)
    • English or Spanish-speaking

    Vaccine Phase

    • Survey response indicated no prior history of HPV vaccination
    • Agrees to return to participating institution for 3 HPV vaccine injections
    • Allergy to any component of the HPV vaccine including yeast and aluminum will not be eligible for the study
    View Trial

    DASRAN: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

    Diseases Treated:

    Parainfluenza virus in immunocompromised patients

    Eligibility:

    • Participant is >12 years of age.
    • Participant is currently on invasive mechanical ventilation or noninvasive positive pressure ventilation or requiring > 2 LPM supplemental oxygen to maintain O2 saturation > 90% due to hypoxemia.
    • Participant is Immunocompromised, as defined by one of the following:
      • Autologous or Allogeneic hematopoietic cell transplantation (HSCT).
      • Lung or lung-heart transplantation.
      • Participant is treated with chemotherapy for hematologic or solid tumor malignancies.
    View Trial

    ED0157: Phase 1 Pediatric PK/PD Study

    A Phase I, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients

    Diseases Treated:

    For patients at risk for blood clots

    Eligibility:

    • Participant has a diagnosis requiring anticoagulant therapy.
    • Participant has completed their standard anticoagulant therapy.
    • Participant is not receiving active therapy for a malignant condition.
    • Participant is less than 18 years of age at the time of consent.
    • Participant and legal guardian agree to food and drug restrictions during study.
    View Trial

    ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

    A Phase 2/3 multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects

    Diseases Treated:

    HIV Infection

    Eligibility:

    • Participant does not have life expectancy of less than 1 year.
    • Participant does not have history of significant drug sensitivity or drug allergy.
    • Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
    • Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
    View Trial

    ESFT13: Therapeutic Trial for Patients with Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors

    Combination Chemotherapy with or without Sorafenib Tosylate and Bevacizumab in Treating Patients with Ewing Sarcoma or Desmoplastic Small Round Cell Tumors

    Diseases Treated:

    Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors

    Eligibility:

    • Diagnosis of Ewing sarcoma and/or desmoplastic small round cell tumor (DSRCT)
    • Less than 25 years of age
    • Has not received previous treatment with radiation therapy or chemotherapy. Emergent radiation therapy to preserve vital organ function is permitted.
    View Trial

    HLHR13: Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma

    Adcetris® (Brentuximab Vedotin) Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High-Risk Pediatric Hodgkin Lymphoma (HL)

    Diseases Treated:

    High-risk Hodgkin lymphoma

    Eligibility:

    • Has high-risk Hodgkin lymphoma
    • 18 years of age or younger
    • Has not received previous treatment for Hodgkin lymphoma
    View Trial

    HOD08: Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma

    Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

    Diseases Treated:

    Hodgkin lymphoma

    Eligibility:

    • Diagnosis of early-stage Hodgkin lymphoma 
    • Hodgkin lymphoma that has not been previously treated
    • 21 years of age or younger
    View Trial

    HODLP: First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin Lymphoma in Children and Adolescents

    Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

    Diseases Treated:

    Lymphocyte predominant Hodgkin lymphoma 

    Eligibility:

    • Diagnosis of early-stage lymphocyte-predominant Hodgkin lymphoma (LPHL)
    • LPHL that has not been previously treated with chemotherapy or radiation therapy
    • 18 years of age or younger

     

    View Trial

    LDKALK: Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

    A Phase I, Open-Label, Dose Escalation Study of LDK378 in Pediatric Patients with Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Novartis Protocol CLDK378X2103

    Diseases Treated:

    Refractory or progressive malignancies

    Eligibility:

    • Age > 12 months and < 18 years.
    • Participant has been diagnosed with a locally advanced or metastatic malignancy that has progressed despite standard therapy, or which no effective standard therapy exists.
    • Specimen is being submitted for molecular pre-screening to test for genetic alteration of ALK and the tumor must carry a genetic alteration of the ALK gene.
    • Participant has adequate liver, kidney, cardiac, and bone marrow function.
    View Trial

    LDTAM: Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

    Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    For survivors of Hodgkin lymphoma

    Eligibility:

    • Females, 25 years of age or older.
    • Participant does not plan to become pregnant in the next 2 years and is not currently breast feeding.
    View Trial

    MEK116: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

    An Open- Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations.

    Diseases Treated:

    Refractory or refractory solid tumor

    Eligibility:

    • Participant is < 18 years at the time of signing the informed consent (in Part A, participants < 2 years of age are not included).
    • Participant has a histologically confirmed solid tumor
    • Participant has a disease that is relapsed or refractory to all potentially curative standard treatment regimens, or has a disease for which there is no standard treatment regimen that is potentially curative.
    View Trial

    MEKPEM: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced Relapsed or Refractory Solid Tumor or Lymphoma

    (Merck study KEYNOTE-051, IND# 110,080, dated 10-15/2014). EudraCT NUMBER: 2014-002950-38

    Diseases Treated:

    Advanced melanoma or PD-L1 positive advanced relapsed or refractory solid tumor or  lymphoma

    Eligibility:

    • Participant has advanced melanoma or PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma
    • Participant of child bearing potential has a negative pregnancy test 72 hours prior to medication administration
    • Participant has appropriate liver and kidney function
    View Trial

    MELBMS: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

    Diseases Treated:

    Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma

    Eligibility:

    • Participant does not have a history of or current immunodeficiency disease, splenectomy or splenic irradiation
    • Participant does not have primary ocular melanoma
    • Participant does not have an uncontrolled infectious disease
    • Participant has not had a prior allogeneic stem cell transplant
    View Trial

    MELPLX: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

    An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of RO5185426 in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600

    Diseases Treated:

    Melanoma

    Eligibility:

    • Patients may have newly diagnosed or recurrent melanoma
    • Patients with histologically confirmed surgically incurable and unresectable Stage IIIC or Stage IV (AJCC) melanoma
    • Patients aged ≥ 12 to ≤ 17 years
    • Patients with active or untreated CNS lesions or history of or known spinal cord compression or carcinomatous meningitis or history of allogeneic bone marrow transplantation or organ transplantation are not eligible for the study

     

    View Trial

    MITREL: A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

    A Phase II Study of Microtransplantation in Patients with Refractory or Relapsed Hematologic Malignancies

    Diseases Treated:

    Refractory or relapsed acute myeloid leukemia (AML), myelodysplatic syndrome (MDS), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia (MPAL)

    Eligibility:

    • Patient should be is less than or equal to twenty-one years of age.
    • Patient has a diagnosis of AML, MDS, ALL, or MPAL that has relapsed or is refractory to chemotherapy or has relapsed after HSCT.
    • Patient has an available PBSC donor.
    View Trial

    NB2012: Therapy for Children with Advanced Stage High-Risk Neuroblastoma

    Anti-GD2 Monoclonal Antibody Hu14.18K322A and Combination Chemotherapy before Autologous Stem Cell Transplant and Radiation Therapy in Treating Younger Patients with Previously Untreated High-Risk Neuroblastoma

    Diseases Treated:

    Neuroblastoma

    Eligibility:

    • Participant is < 19 years of age at the time of study enrollment.
    • Participant has newly diagnosed, advanced stage, high-risk neuroblastoma.
    • Participant has histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamine.
    • Participant has adequate renal and hepatic function.
    View Trial

    NHL16: Study for Newly Diagnosed Patients with Acute Lymphoblastic Lymphoma

    Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Lymphoma

    Diseases Treated:

    Acute lymphoblastic leukemia

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed lymphoblastic lymphoma
    • Has received one week or less prior treatment for lymphoblastic lymphoma
    View Trial

    P1093: Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents

    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

    Diseases Treated:

    Human Immunodeficiency Virus

    Eligibility:

    • Participant is ≥ 4 weeks to < 18 years of age.
    • Confirmed HIV-1 infection
    • HIV treatment experienced (current or past treatment with HIV medications) patient
    View Trial

    P1TEAM: Medication Adherence in Human Immunodeficiency Virus (HIV)

    Targeting Enhanced Adherence to Medication: A Pilot Study in Adolescents and Young Adults with Human Immunodeficiency Virus (HIV)

    Diseases Treated:

    Human immunodeficiency virus (HIV)

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    PANSTAT: A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

    A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies

    Diseases Treated:

    Relapsed acute lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin disease [HD] and non-Hodgkin’s lymphomas [NHL]

    Eligibility:

    • Patient must be greater than 1 and less than or equal to 21 years of age at the time of enrollment;
    • Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
    • Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.
    View Trial

    PBTC29: Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    A Phase I and Phase II and Re-treatment Study of AZD6244 for Recurrent or Refractory Low Grade Glioma (PBTC-029)

    Diseases Treated:

    Gliomas

    Eligibility:

    • Participant is ≥ 3 but ≤ 21 years of age at registration.
    • Participant has a diagnosis of low grade glioma (Grades I & II) or optic pathway gliomas with clinical and/or radiographic evidence of progression.
    • Participant received last fraction of local irradiation to the primary tumor ≥ 12 weeks prior to registration, or does not apply.
    View Trial

    PBTC33: Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

    A Phase I/ II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)

    Diseases Treated:

    Newly diagnosed diffuse intrinsic pontine gliomas (DIPG)

    Eligibility:

    • 21 years of age or younger
    • Newly diagnosed diffuse intrinisic pontine glioma  (DIPG)
    • Able to swallow oral medications
    • No prior treatment with chemotherapy, immumotherapy or radiation
    • No history of seizures
    View Trial

    PBTC39: Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

    Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma (PBTC-039)

    Diseases Treated:

    Unresectable or recurrent craniopharyngioma

    Eligibility:

    • Participant has a histologically verified diagnosis of craniopharyngioma.
    • Participant has recovered from acute toxicities of all prior therapy before entering this study.
    • Participant has not received prior interferon, either systemic or into the tumor cyst.
    • Participant does not have evidence of metastatic tumor.
    View Trial

    PBTC42: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

    Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors

    Diseases Treated:

    Retinoblastoma protein 1 (Rb1) positive recurrent, progressive, or refractory central nervous system tumors

    Eligibility:

    • Participant between four (4) and twenty-one (21) years of age at time of enrollment.
    • Participant has histologically confirmed Rb1 positive recurrent, progressive, or refractory CNS tumor or DIPG.
    • Participant with a neurological deficit that is stable for at least one (1) week prior to enrollment.
    • Participant has received last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to enrollment.
    • Participant has received last fraction of focal irradiation > two (2) weeks prior to enrollment.
    View Trial

    PMVOC: Pain Management of Vaso-Occlusive Crisis in Children and Young Adults with Sickle Cell Disease

    Diseases Treated:

    Sickle Cell Disease

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    View Trial

    PNOC001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children (CC #120817)

    Diseases Treated:

    Recurrent or progressive low grade gliomas (brain tumors)

    Eligibility:

    • Participant is three (3) to twenty-one (21) years of age.
    • Patient has refractory, progressive or recurrent confirmed low-grade glioma (WHO grade I or II) that was confirmed histologically at initial diagnosis.
    • Participant received his or her last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration, or at least six (6) weeks if nitrosurea.
    • Participant received his or her last dose of other investigational or biological agent more than seven (7) days prior to study entry.
    View Trial

    PREVENT: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial

    Diseases Treated:

    Congestive heart failure

    Eligibility:

    • Participant is > 16 years of age.
    • Participant had cancer diagnosis < 21 years of age.
    • Participant has lifetime cumulative anthracycline dose > 300 mg/m2.
    • Participant is > 2 years since completion of treatment for cancer.
    View Trial

    RADIANT: Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas

    A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation In Children with Relasped or Refractory Solid Tumors

    Diseases Treated:

    Relapsed or refractory solid tumors or lymphomas

    Eligibility:

    • Between the ages of 2 and 21 years
    • Solid tumor or lymphoma as primary cancer
    • Cancer that has come back or did not respond to previous chemotherapy
    • No heart, kidney or liver problems
    View Trial

    RELHEM: Sorafenib Tosylate, Cytarabine, and Clofarabine in Treating Patients with Refractory or Relapsed Hematologic Malignancies

    A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies

    Diseases Treated:

    Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia

    Eligibility:

    • Patient must have acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (either AML or ALL), AML with prior myelodysplastic syndrome (MDS),myelodysplastic/myeloproliferative neoplasms, or biphenotypic leukemia.
    • Patients must meet one of the following criteria:
      • First or greater relapse
      • Refractory to 1 or more courses of induction or reinduction chemotherapy
      • First or greater relapse after allogeneic hematopoietic stem cell transplantation (HSCT).

     

    View Trial

    RELHEM2: Crenolanib and Sorafenib Tosylate in Treating Patients with Refractory or Relapsed Hematologic Malignancies

    A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination with Sorafenib in Patients with Refractory or Relapsed Hematologic Malignancies (ARO-008)

    Diseases Treated:

    Refractory or relapsed hematologic malignancies (leukemia)

    Eligibility:

    • Between the ages of 1 and 25 years
    • FLT3-mutated AML that has returned or did not respond to previous chemotherapy
    • No history of HIV infection, hepatitis B, or hepatitis C
    View Trial

    RELMLL: A Phase II Study of Bortezomib and Vorinostat in Patients with Refractory or Relapsed MLL Rearranged Hematologic Malignancies

    Diseases Treated:

    Relapsed or refractory leukemia / lymphoma

    Eligibility:

    This clinical trial has both inclusion and exclusion criteria. See Eligibility Requirements in the full trial for specifics.

    View Trial

    RT2CR: Limited Surgery and Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors

    A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma after Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years of age or younger
    • Diagnosis of craniopharyngioma 
    • Has not been previously treated with radiation therapy
    View Trial

    SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

    A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

    Diseases Treated:

    Metastatic sarcomas

    Eligibility:

    • Participant has histologically or cytologically confirmed diagnosis:
      • Nonrhabdomyosarcoma of soft tissue
      • Ewing sarcoma
      • Osteosarcoma at any site
    • Participant must be greater than 3 years of age and < 40 years of age.
    • Participant has not had any prior radiotherapy to the treatment site.
    View Trial

    SELHEM: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    Diseases Treated:

    Relapsed or refractory leukemia or hematologic malignancies

    Eligibility:

    • Up to 21 years of age
    • Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) or mixed phenotype acute leukemia (MPAL) that has come back or did not respond to previous treatment
    • No history of HIV infection
    View Trial

    SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Diseases Treated:

    Croup

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial

    SJATRT: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

    Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (ATRT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed ATRT

    Diseases Treated:

    Brain Tumor : Recurrent, progressive, or newly diagnosed atypical teratoid rhabdoid brain tumors (ATRT)
    Solid Tumor : Progressive extra-CNS malignant rhabdoid solid tumors (MRT)

    Eligibility:

    • Has one of these types of tumors:
      • Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) or synchronous extraneural ATRTs
      • ATRTs or malignant rhabdoid tumors (MRTs) that have come back after previous treatment (recurrent disease)
      • ATRTs or MRTs that are growing after previous treatment (progressive disease)
    • 21 years of age or younger
    View Trial

    SJGD2: Monoclonal Antibody Therapy in Treating Younger Patients with Relapsed or Refractory Neuroblastoma, Osteosarcoma, or Melanoma

    A Phase I Trial of the Humanized Anti-GD2 Antibody(HU14.18K322A) in Children and Adolescents with Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

    Diseases Treated:

    Neuroblastoma, osteosarcoma, melanoma or Ewing sarcoma

    Eligibility:

    • Up to 21 years of age
    • Diagnosis of neuroblastoma, melanoma, osteosarcoma  or Ewing sarcoma that has come back or did not respond to previous treatment
    • Any uncontrolled infection
    View Trial

    SJHG12: Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma

    Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants with Diffuse Intrinsic Pontine Glioma and High-Grade Glioma

    Diseases Treated:

    Progressive or recurrent pontine glioma or high-grade glioma

    Eligibility:

    • Between 2 and 21 years of age
    • Diagnosis of diffuse intrinsic pontine glioma (DIPG) or high-grade glioma
    View Trial

    SJMB12: A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma/PNET

    Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Medulloblastoma

    Diseases Treated:

    Medulloblastoma (includes all variants of medulloblastoma and posterior fossa PNET)

    Eligibility:

    • Diagnosis of newly medulloblastoma
    • Must be least 3 but not more than 22 years of age
    • Has not received previous treatment with radiation therapy or chemotherapy
    • Must start treatment within 36 days of surgery to remove the tumor
    View Trial

    SJRET6: Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma

    Protocol for the Study and Treatment of Participants with Intraocular Retinoblastoma

    Diseases Treated:

    Retinoblastoma

    Eligibility:

    • Newly diagnosed retinoblastoma that has not spread beyond the eye
    • Has not received previous treatment with chemotherapy or radiation therapy
    • Patients who have been diagnosed with retinoblastoma in one eye who did not receive chemotherapy, but then developed retinoblastoma in the opposite eye
    View Trial

    SJYC07: Risk-Adapted Therapy in Treating Young Children with Brain Tumors

    Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma

    Diseases Treated:

    ATRT, PNET, medulloblastoma and other embryonal brain tumors, high-grade glioma, choroid plexus carcinoma or ependymoma

    Eligibility:

    • Newly diagnosed brain tumor or tumor of the central nervous system and less than 3 years of age
    • Children between 3 and 5 years old with medulloblastoma  that has not spread  into the fluid that surrounds the brain and spinal cord can also be treated on this trial
    • No prior radiation therapy or chemotherapy
    View Trial
  8. DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

    Diseases Treated:

    Solid tumors

    Eligibility:

    This is a non-therapeutic clinical trial that is only open to St. Jude patients.

    • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy. 
    • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
    • Participant meets institutional MRI safety screening requirements. 
    • Participant has not undergone primary tumor resection prior to arrival to St. Jude
    View Trial

    RERTEP: Surgery and Second-Course Radiation Therapy in Treating Younger Patients With Recurrent Ependymoma

    A Phase II Trial of Surgery and Fractionated Re-irradiation for Recurrent Ependymoma

    Diseases Treated:

    Recurrent ependymoma

    Eligibility:

    • Participant aged 1-21 years at the time of enrollment.
    • Participant has histologically proven progressive Ependymoma after prior focal irradiation.
    • Participant did not receive prior craniospinal irradiation.
    • Participant is not pregnant.
    View Trial

    RMS13: Chemotherapy, Surgery, and Radiation Therapy in Treating Patients with Newly Diagnosed, Localized Rhabdomyosarcoma

    Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients with Low and Intermediate Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

    Diseases Treated:

    Rhabdomyosarcoma (Low-risk and intermediate-risk)

    Eligibility:

    • Must have newly diagnosed rhabdomyosarcoma
    • Less than 22 years of age
    • Has not received previous treatment with chemotherapy or radiation therapy
    View Trial

    RT2CR: Limited Surgery and Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors

    A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma after Radical Resection

    Diseases Treated:

    Craniopharyngioma

    Eligibility:

    • 21 years of age or younger
    • Diagnosis of craniopharyngioma 
    • Has not been previously treated with radiation therapy
    View Trial

    SBRT1: Stereotactic Radiation Therapy for Pediatric Sarcomas

    A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

    Diseases Treated:

    Metastatic sarcomas

    Eligibility:

    • Participant has histologically or cytologically confirmed diagnosis:
      • Nonrhabdomyosarcoma of soft tissue
      • Ewing sarcoma
      • Osteosarcoma at any site
    • Participant must be greater than 3 years of age and < 40 years of age.
    • Participant has not had any prior radiotherapy to the treatment site.
    View Trial
  9. SENDAI: A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity

    Diseases Treated:

    Croup

    Eligibility:

    • Child is greater than or equal to twelve (12) months and less than twenty-four (24) months.
    • Child has adequate blood, liver and kidney function.
    • Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition.
    View Trial